Co-Authors
This is a "connection" page, showing publications co-authored by Sophie Trouillet-Assant and Alexandre Belot.
Connection Strength
1.708
-
Correction: Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. J Exp Med. 2021 Oct 04; 218(10).
Score: 0.241
-
Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients. Clin Transl Immunology. 2021; 10(8):e1327.
Score: 0.241
-
Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. J Exp Med. 2021 10 04; 218(10).
Score: 0.240
-
Clinical and laboratory characteristics of symptomatic healthcare workers with suspected COVID-19: a prospective cohort study. Sci Rep. 2021 07 22; 11(1):14977.
Score: 0.239
-
Polyclonal expansion of TCR Vbeta 21.3+ CD4+ and CD8+ T cells is a hallmark of Multisystem Inflammatory Syndrome in Children. Sci Immunol. 2021 05 25; 6(59).
Score: 0.237
-
Type I IFN immunoprofiling in COVID-19 patients. J Allergy Clin Immunol. 2020 Jul; 146(1):206-208.e2.
Score: 0.220
-
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021 08 19; 6(62).
Score: 0.060
-
Refining "Long-COVID" by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection. Infect Dis Ther. 2021 Sep; 10(3):1747-1763.
Score: 0.060
-
Type-I Interferon assessment in 45 minutes using the FilmArray® PCR platform in SARS-CoV-2 and other viral infections. Eur J Immunol. 2021 04; 51(4):989-994.
Score: 0.058
-
Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 10 23; 370(6515).
Score: 0.057
-
Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia. Cell Rep Med. 2020 07 21; 1(4):100059.
Score: 0.056